SGS proderm GmbH
Hamburg, Germany
NCT Number: NCT05840172
The investigation is to evaluate the effectiveness of benzocaine in two NRL condoms compared with a standard NRL control without benzocaine in prolonging time to ejaculation in healthy adult men who feel they ejaculate too quickly during vaginal sex.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Hamburg, Germany
In this investigation, two NRL condoms with benzocaine paste (Test condom A and Test condom B) will be evaluated against a standard NRL male condom (Control condom) in prolonging time to ejaculation in healthy adult men who feel they ejaculate too quickly during vaginal sex.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Main Inclusion Criteria:
Main Exclusion Criteria:
In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
Time frame: 4 weeks for each assessment period (intervention duration)
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom A compared to the Control NRL Condom, over a 4-week assessment period.
This outcome was to measure the per participant's average IELT time per condom type. The Intravaginal Ejaculation Latency Time (IELT) is the duration from the start of vaginal entry (vaginal penetration into the female partner) until the start of intravaginal ejaculation (release of semen). It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model.
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom B compared to the Control NRL Condom, over a 4-week assessment period.
This outcome was to measure the per participant's average IELT time per condom type. It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model.
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the proportion of participants who achieved an increase of 2, 3 and 4 minutes from baseline in each of the Test Condom A and Test Condom B compared to the Control NRL Condom.
The odds ratio compares the odds of achieving a given duration increase (e.g., ≥2 minutes) with Test Condom A or B to the odds of achieving the same increase with the Control Condom. An odds ratio greater than 1 suggests the test condom is more effective than the control in helping participants reach that milestone.
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
The outcome was assessed by the measure of EMSEX (Event-level Male Sexual) pleasure scale questionnaire, a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. EMSEX pleasure scale is a 11-item scale which assesses sexual pleasure at the event level. For each item, the range spans the entirety of the potential range from 0 (zero) to 100 (one hundred).
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
The outcome was assessed by the measure of Patient Global Impression of Change (PGIC), a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. The PGIC is a 7-point response scale (Very much better, Better, Little better, No change, Little worse, Worse, Very much worse).
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Upon completion of each condom assessment period, each participant was required to complete a SPQ. The questionnaire collected the following information (including but not limited to): experience with condom use, acceptability, preference and tolerability.
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Number of clinical failure events per usages (clinical slippage or clinical breakage) reported by participants. The number of outcomes are based on the number of sexual encounters while wearing one of the three condoms being tested.
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 19 weeks
Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant.
The result is presented by the counts of all AEs sorted by SOC and PT for male participants.
This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 19 weeks
Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant.
The result is presented by the counts of all AEs sorted by SOC and PT for male participants.
This outcome measure data was collected and analyzed for 150 female participants.
Reckitt Benckiser Healthcare (UK) Limited
Industry
An Open Label, Randomised, 3-way Cross-over, Single-centre, Clinical Investigation to Evaluate the Effectiveness of Benzocaine in Two NRL Condoms Compared With a Standard NRL Control Without Benzocaine in Prolonging Time to Ejaculation in Healthy Adult Men Who Feel They Ejaculate Too Quickly During Vaginal Sex
Acronym: NRL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715448
Benign Prostatic Hyperplasia, Ejaculatory Dysfunction
Banī Suwayf, Beni Suef Governorate, Egypt
View Trial DetailsNCT05650853
Ejaculatory Dysfunction, Genital Diseases
Toulouse, France
View Trial DetailsNCT07385222
Ejaculatory Dysfunction, Female Urogenital Diseases and Pregnancy Complications
Bolu, Merkez, Turkey (Türkiye)
View Trial DetailsNCT05914519
BPH, Ejaculatory Dysfunction
Sohag, Sohag Governorate, Egypt
View Trial Details